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Objective: Treatment of differentiated thyroid carcinoma (DTC) includes suppression of TSH with levothyroxine
therapy, which may negatively influence bone mineral density (BMD), but the effects are controversial. We aimed to
evaluate the relationship between TSH-suppressive therapy and BMD in postmenopausal women with DTC.
Methodology: Cross-sectional study that assessed BMD by densitometry and risk factors for decreased BMD in 109
postmenopausal women under TSH-suppressive therapy for DTC, compared to an age-matched euthyroid women
control group. Conditions that might have affected BMD were exclusion criteria.
Results: Patients were 58.4 ± 8.3 years-old, mean serum TSH was 0.21 ± 0.28μIU/ml. In BMD evaluation, T-scores
were −1.09 ± 1.43 SD (lumbar spine) and −0.12 ± 1.18 SD (total femur). No significant differences were found between
lumbar or femoral T-scores of patients and control group. Multivariate logistic regression analysis evidenced that low
BMI and low mean TSH levels (assessed in the year of BMD measurement) were factors significantly related to lower
lumbar and spinal BMD.
Conclusion: Although low TSH levels and low BMI were correlated with lower BMD, it was not observed an increased
prevalence of osteopenia or osteoporosis in this cohort of post-menopausal women under levothyroxine treatment for
DTC, when compared to age-matched control women. Nevertheless, such risk factors should be carefully observed in
individual patients at high risk of decrease in BMD.
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Suppression of thyroid-stimulating hormone (TSH) with
supraphysiological doses of levothyroxine (LT4) is one
component of the treatment of differentiated thyroid
carcinoma (DTC), after surgery and radioiodine therapy,
aiming to reduce the risk of tumor recurrence [1]. In
recent years, guidelines for TSH suppression therapy in
the treatment of DTC have changed, due to the excellent* Correspondence: thaismelo79@hotmail.com
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course [2]. TSH suppression is recommended, but there
is still no consensus about the ideal concentration of
TSH for DTC patients. Besides the beneficial effects of
TSH suppression in reducing tumor recurrence, poten-
tial risks should be considered [2].
The deleterious consequences of TSH suppression in
the cardiovascular system are well-established [2, 3],
but subclinical thyrotoxicosis may also have a negative
influence on bone metabolism. Nevertheless, the
magnitude of the effect and influence of additional
factors on bone mineral density (BMD) of thosearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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implications of TSH suppression on BMD in patients
with DTC are conflicting [2]. Particularly in postmeno-
pausal women, several authors have reported a negative
effect of long-term TSH suppressive treatment on the
BMD of patients with DTC [4–7], while other studies have
not confirmed such negative effect [8–11]. BMD analysis
is important because it is correlated with the risk of frac-
tures in postmenopausal women [12]. We have not found
studies with definite results about the correlation of TSH
suppressive therapy for DTC and osteoporosis or osteope-
nia in post-menopausal women [13].
Methods
The objective of this study was to evaluate the relation-
ship between TSH suppressive therapy and BMD in
postmenopausal women with DTC.
This investigation was a cross-sectional study with 109
postmenopausal women from a single center specialized
in treatment of thyroid neoplasia. Patients were in
follow-up for DTC, according to updated guidelines
during the years. It is important to mention that the
guidelines for treating DTC have changed along the time
and some recommendations, such as the target TSH
level, were modified during patients follow-up. All
patients had their BMD evaluated between 2009 and
2011, in one single time. Patients were compared to a
control group composed of postmenopausal euthyroid
women, matched by age at the time of BMD assessment.
The control group was obtained from the database of
the bone densitometry unit of the Division of Nuclear
Medicine in the same institution. Women with hyper-
thyroidism or hyperprolactinemia, permanent post-
surgical hypoparathyroidism, intestinal malabsorption,
rheumatoid arthritis, osteoarthritis, chronic kidney
disease, prolonged immobilization, other malignant
neoplasia or chronic use of corticosteroid and anticon-
vulsivants anytime during their lifetime were excluded
from both groups, due to potential interference in
BMD. After signing the informed consent form, pa-
tients were surveyed in order to assess risk factors that
could be associated to low BMD, according to the
National Osteoporosis Foundation [12] and the World
Health Organization (WHO) guidelines [14]. Questions
included smoking history, family history of osteopor-
osis, age at menarche and menopause, previous use of
oral contraceptives, corticosteroids and anticonvulsants
drugs, hormone replacement therapy for menopause,
physical activity, and daily calcium intake. The study
was approved by the local Ethics Committee, according
to the 3rd edition of the Guidelines on the Practice of
Ethical Committees in Medical Research.
Lumbar spine and femoral BMD were measured with a
“Hologic DXA Discovery Wi” densitometer. We analyzedlumbar spine (L1-L4) and total femur T-scores, and diag-
nosis was done according to the WHO criteria for the
diagnosis of osteoporosis and osteopenia in postmeno-
pausal women [12, 14].
We also analyzed TSH levels (chemiluminescence
method, sandwich technique, Elecsys TSH-Roche,
reference value: 0.40–4.5 μIU/ml) and free thyroxine
(FT4-electrochemiluminescence method, competition
principle, Elecsys FT4-Roche, reference value: 0.9–
1.8 ng/dl). All TSH and FT4 levels values were
obtained in the year previously to the BMD assess-
ment for each patient were included in the analysis
(ranging from 3 to 4 values for each patient). Besides
that, we considered for the study all TSH level values
in each patient’s file in order to evaluate the period of
time each patient was exposed to different degrees of TSH
suppression (<0.001 μIU/ml or <0.1 μIU/ml). Serum PTH
was assessed in 80 patients by electrochemiluminescence
method, reference value of 15-65 pg/ml.
Sample size calculation was done after a pilot analysis of
20 patients and 20 control individuals. Based on that, the
minimal number of subjects for each group was 90 (alfa
and beta error of 0.05 and 0.2, respectively). For the com-
parison of categorical variables between the main groups,
we used Pearson’s chi-square test. Mann–Whitney test
was used for the comparison of numerical variables be-
tween the two groups. The Spearman correlation coeffi-
cient was used to analyze the relationships between
numerical variables. For the study of factors related to the
BMD values, linear regression analysis was used, with uni-
variate and multivariate models and stepwise criteria for
variable selection. The statistical tests were performed in
the SAS 9.1.3 System (SAS Institute Inc, 2002–2003,
Cary, NC, USA), and the level of significance for the
statistical tests was 5 % (p < 0.05).
Results and discussion
Out of 128 patients evaluated, 109 met the inclusion cri-
teria. Histology of CDT was papillary thyroid carcinoma
in 91 patients (83.49 %), follicular thyroid carcinoma in
17 patients (15.59 %), and insular carcinoma in one
patient (0.92 %). The mean follow-up time was 88 ±
70.6 months, ranging from 12 to 359 months since start
of FT4 therapy. The baseline characteristics of the sub-
jects in patients and control groups were comparable
(including age, age at menopause, post-menopausal time,
use of post-menopausal hormone therapy), except for
mean TSH level (Table 1).
The average calcium intake reported by the patients
was 470.18 ± 346.69 mg/day, and the mean PTH value
(n = 80) was 38.63 ± 13.02 pg/ml. Fifty-four patients
(49.54 %) reported use of oral contraceptives in the past,
for an average of 5.87 ± 4.85 years, and 19.20 % of the pa-
tients reported previous or current use of postmenopausal
Table 1 Baseline characteristics of the patients with thyroid cancer and the control group
Variable Patients Control group P value
Age (years-old) 58.43 ± 8.37 58.43 ± 8.40 0.968
Age at menopause (years-old) 47.19 ± 5.12 46.51 ± 5.33 0.235
Post-menopause time (years) 11.24 ± 9.54 11.93 ± 8.92 0.407
Caucasian (%) 92.6 91.74 0.801
Post-menopausal hormonal therapy (%) 19.2 27.5 0.150
BMI (kg/m2) 27.90 ± 4.51 28.33 ± 4.77 0.667
TSH (μIU/ml) 0.21 ± 0.28 2.27 ± 1.02 <0.001
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follow-up time in which patients remained with more sup-
pressed TSH levels (<0.001 μIU/ml) was 14 ± 12 %. During
39 ± 22 % of the follow-up time, the patients presented
mean TSH level <0.1 μIU/ml. At the time of BMD evalu-
ation, 24 patients (22.02 %) were being followed for 12–35
months, 20 (18.35 %) for 36–59 months, 39 (35.78 %) for
60–119 months, and 26 (23.85 %) for 120 months or more.
The mean T-scores of the patients were −1.09 ± 1.43
standard-deviations (SD) in L1 - L4 and −0.12 ± 1.18
SD in total femur. 19.2 % of the patients were diag-
nosed with osteoporosis, 40.4 % with osteopenia, and
40.4 % presented a normal BMD. The mean T-scores
of the control group were −1.11 ± 1.3 SD in L1 - L4
and −0.37 ± 1.06 SD in total femur. The BMD diagno-
sis in the control group showed osteoporosis in 15.5 %
of the women; osteopenia in 45 %, and 39.5 %
presented a normal BMD. No significant differences
were found between the lumbar (p = 0.940) or femoral
(p = 0.105) T-scores of the patients and the control
group. No significant differences were found between
the two groups regarding the frequency of diagnosis of
osteoporosis, osteopenia, or normal BMD (χ2 = 0.70,
degree of liberty =2, p = 0.704).a
Fig. 1 Factors with significant correlation to L1-L4 T-score in thyroid cancer p
and L1-L4 T-scoreUnivariate logistic regression identified significant
positive correlations between T-score in L1-L4 and body
mass index (BMI) (p < 0.001, R2 0.1372) and between T-
score in L1-L4 and the mean TSH values (p = 0.042 and
R2 0.038, Fig. 1a and b). Considering the T-score in total
femur, there were significant correlations with BMI
(p < 0.001, R2 = 0.2599), use of oral contraceptive in
the past (p = 0.020, R2 = 0.0496) and mean TSH values
(p = 0.010, R2 = 0.0605), as demonstrated in Fig. 2a, b
and c.
Multivariate logistic regression analysis evidenced as
factors significantly related to lower lumbar BMD:
low BMI (p < 0.001; R2 = 0.15) and low mean TSH
value (p = 0.021; R2 = 0.0423). For total femur, the fac-
tors that significantly affected the BMD were low
BMI (p < 0.001; R2 = 0.26), low TSH value (p < 0.001;
R2 = 0.07), and the history of never having used oral
contraceptive (p = 0.007; R2 = 0.04). No relationship
was found between BMD and mean serum FT4 levels.
Furthermore, the total period of time in which patients
remained with TSH levels <0.001μIU/ml or <0.1μIU/ml
during follow-up had no significant association to BMD
parameters. Only the TSH level measured in the year
prior to BMD assessment showed correlation to BMD.b
atients under TSH supressive therapy. a BMI and L1-L4 T-score. b TSH
a b
c
Fig. 2 Factors with significant correlation to total femur T-score in thyroid cancer patients under TSH supressive therapy. a BMI and total femur
T-score. b TSH and total femur T-score. c Oral contraceptive and total femur T-score
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cant positive correlation between BMI and L1-L4 T-
score (p = 0.040; R2 = 0.0358) and between BMI and
total femur T-score (p < 0.001; R2 = 0.1578).
Lumbar and spinal T-scores of postmenopausal
women treated with exogenous LT4 therapy due to DTC
were not lower than the T-scores of the control group
with the same age and similar baseline characteristics in
euthyroid state. This finding is in accordance with other
previously published analyses, generally performed in
smaller samples. Our analysis was based on a sample
size calculation and included a greater number of post-
menopausal women than most of the published studies.
A meta-analysis, published in 2006, assessed the risk
of osteoporosis in DTC patients treated with TSH-
suppressive doses of LT4, and included 14 cross-
sectional studies (n = 10 to 44) and four longitudinal
studies (n = 10 to 46) involving postmenopausal women
[15]. The association between TSH-suppressive therapy
and reduced BMD was found in only four out of 14
cross-sectional studies and two out of four longitudinal
studies [4, 16, 17]. Eftkhari et al. also reported no signifi-
cant association between TSH suppressive therapy and
BMD reduction in 33 postmenopausal women compared
to an age-matched euthyroid control group [8]. Lee et al.analyzed the BMD of a group of 94 Korean women re-
ceiving LT4 as part of treatment of DTC (66.7 % of them
in postmenopausal state). They were divided into three
groups according to TSH levels (≤0.001 μIU/mL, be-
tween 0.001 and 0.17 μIU/mL, and >0.17 μIU/mL) and
no significant decrease was detected in BMD or bone
turnover markers according to TSH level or even FT4
level. Also, the prevalence of osteoporosis and osteope-
nia was not different among groups [11].
A prospective study compared 144 women with
TSH-suppressive therapy for DTC (mean TSH level
0.07 ± 0.10 μIU/ml) with 127 women with DTC without
TSH-suppression treatment (mean TSH level 3.14 ±
1.69 μIU/ml) and demonstrated that BMD were lower
only in patients ≥50 years-old that were treated with
TSH-suppressive therapy for at least one year [6]. More
recently, investigators from the Memorial Sloan-
Kettering Hospital, in the United States, demonstrated
that in a group of 771 patients (569 women, mean age
48 ± 14 years-old) with CDT at ATA low or intermedi-
ate risk of recurrence, followed by 6.5 years, the pa-
tients treated to reach a median TSH level ≤0.4 mIU/L
were at increased risk of a composite outcome of atrial
fibrillation and osteoporosis compared to those not
suppressed [7]. Although the postmenopausal state of
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authors reported a synergistic effect between increasing
age and TSH suppression [7].
Many reasons may explain the discrepancy between the
results, such as different follow-up time, daily calcium
intake or sunlight exposure, as well as characteristics of
the different control groups. But one of the most import-
ant factors may be the different TSH levels observed in all
those studies.
TSH receptors have been identified in osteoclasts and
osteoblasts [18], and the role of TSH on bone metabolism
has been studied. Abe et al. demonstrated that TSH in-
hibits osteoclastogenesis and also stimulates apoptosis of
mature osteoclasts [19]. Besides that, they demonstrated
that TSH can also inhibit osteoblasts’ differentiation, sug-
gesting that TSH can modulate bone formation and re-
sorption independently [19]. The authors showed that a
50 % reduction in the number of TSH receptors in mice
could lead to osteoporosis. Although the animals were
treated with thyroid hormones in the experiment, they ex-
hibited a high rate of bone remodeling and decreased
BMD, likely due to the deficient action of TSH on osteo-
blasts and osteoclasts [19]. Other animal studies con-
firmed that the absence of TSH signaling contributes to
bone loss. Baliram et al. analyzed the skeletal phenotypes
of wild-type and TSH-receptor knockout mice that were
rendered hyperthyroid. They found that the hyperthyroid
mice without TSH receptor had greater bone loss and
resorption than hyperthyroid wild-type mice and they also
identified a TSH-like factor that may confer osteoprotec-
tion [20]. Sun et al. further evaluated the mechanisms by
which deficient TSH signaling affects the bone and re-
ported that the skeletal actions of TSH deficiency are
mediated, in part, through TNFα, in mice [21].
The hypothesis of a direct association of TSH levels and
BMD was validated in a large cohort of postmenopausal
women in the third “U.S. National Health and Nutrition
Examination Survey” (NHANES III). The study showed a
significant association between higher TSH levels and
higher BMD, even when TSH levels were within the nor-
mal range [22]. Baqi et al. also showed that in a group of
114 postmenopausal women, those with normal TSH level
had higher BMD than those with TSH level below the nor-
mal range, regardless of the FT4 level [23]. These findings
are consistent with the hypothesis that TSH may have a
direct effect on BMD in postmenopausal women. Simi-
larly, data from the present study showed a direct associ-
ation between TSH levels and BMD.
In our study, mean TSH levels assessed in the year prior
to BMD analysis was not so suppressed because we in-
cluded patients who were being followed by long times
(mean follow-up time of 7.3 years). Such patients would
not require very intensive TSH suppression, according to
the guidelines [1]. Nonetheless, all of our patients havegone through a period of more suppressed TSH level after
initial treatment and we could quantify the amount of
time they were exposed to very low and moderately low
TSH level. The number of months the patients were ex-
posed to different degrees of TSH suppression was not
correlated to patients’ BMD, suggesting the potential dy-
namic characteristic of bone tissue. It is possible to argue
that low TSH level can reduce BMD in the short-term
and there could be a possible recovery in BMD after in-
creasing TSH levels during their follow-up. This would
explain why only the TSH measured in the year before
BMD assessment was related to lower BMD, and not the
number of months that the patients were exposed to
lower suppressed TSH level.
It was already shown the possibility of recovering the
lumbar and femoral BMD in patients with reverted hyper-
thyroidism after one year of carbimazole treatment, in-
cluding postmenopausal women [24], as well as the partial
recovery of BMD after 7.5 months of treatment with
methimazole [25]. Also in postmenopausal women with
subclinical hyperthyroidism who were treated with radio-
iodine therapy, a prospective study showed an increase in
lumbar and femoral BMD one year after TSH level were
normal, and the recovery remained for up to two years of
follow-up [26]. Another prospective study performed with
16 postmenopausal women with subclinical hyperthyroid-
ism showed an increase in the forearm BMD two years
after the normalization of TSH level with methimazole
treatment [27]. Similarly, the postmenopausal patients
with exogenous subclinical thyrotoxicosis evaluated in our
study could also have recovered BMD after some increase
in TSH level during follow-up. The BMD assessment in
the moment when TSH was less suppressed (average of
0.21 ± 0.28 μUI/ml in this study) was associated to higher
average T-scores. Possibly, if evaluation was performed
in a moment when average TSH was lower, the average
T-scores could have been lower.
In an attempt to identify other predictive risk factors
for low BMD in our patients, we also examined charac-
teristics that could be related to bone metabolism. Low
BMI, which is a known risk factor for low BMD [12, 14],
was associated with lower lumbar and spinal BMD, both
independently and in association with lower TSH level.
Interestingly, the mean BMI of the patients and the
control group was in the overweight range, which could
be considered even a protective factor for BMD [14].
Limitations of our study include the lack of follow-up
BMD assessments to allow understanding of T-scores evo-
lution during the time, but this was a cross-sectional
study, similarly to the majority of the published studies on
the subject. Although some patients had previous BMD
evaluation, they were not performed in standardized
methods to allow comparisons. Another limitation was
the heterogeneity of the patients, including follow-up
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less suppressed mean TSH levels. Inclusion of patients
with one year of follow-up seems to be adequate, since
Sugitani et al. demonstrated decreased BMD in postmeno-
pausal women with at least one year of TSH-suppressive
therapy [6]. Despite the low average daily calcium intake
referred by the patients, this was not correlated with low
BMD, and patients were oriented to adequate their cal-
cium intake. Other analysis, such as serum vitamin D
levels and serum FT3 levels were not performed in this
study, and PTH measurements were performed only in
patients, not in control group. So, the interpretation of
such data was limited in our study.
Conclusions
Although we could not identify differences in the BMD
of postmenopausal women under LT4 therapy for DTC
versus the age-matched control group, we identified
that the main risk factors for low lumbar and femoral
BMD in that population were BMI and TSH levels, as
well as oral contraceptive previous use for femoral
BMD. Considering the results of the current study, we
suggest that TSH may exhibits its deleterious effect on
BMD only when levels are really suppressed. When
TSH levels are raised, the BMD may be recovered. Our
data reinforces previous findings, indicating that TSH
suppression is a risk factor for osteoporosis, and the in-
terventions in the treatment of DTC should avoid
harmful effects, when possible.
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